帕利哌酮缓释片与利培酮治疗精神分裂症和分裂样精神病的对照研究

目的：观察帕利哌酮缓释片（芮达）与利培酮治疗精神分裂症和分裂样精神病临床疗效、社会功能差异。方法：82例符合诊断标准的精神分裂症或精神分裂样精神病患者被随机分为帕利哌酮缓释片组（n=42）与利培酮组（n=40）进行4周的治疗和观察,在治疗后第1周末、第2周末、第3周末、第4周末比较两组之间阳性与阴性症状量表（PANSS）减分率、临床疗效总评量表（CGI）减分率和个体和社会功能量表（PSP）分值的差异。结果：PANSS减分率,帕利哌酮缓释片组在治疗后第1周末、第2周末、第3周末、第4周末均明显高于利培酮组,差异有统计学意义（P〈0.05）;治疗后第4周末,CGI减分率帕利哌酮缓释片组明显高于利培酮组,差异有统计学意义（P〈0.05）;PSP分值,帕利哌酮缓释片组在治疗后第1周末、第2周末、第3周末、第4周末均明显高于利培酮组,差异有统计学意义（P〈0.01）。结论：帕利哌酮缓释片可以明显改善精神分裂症和分裂样精神病患者的精神病性症状及社会功能。

Comparing studying on efficacy between paliperidone extended-release tablets and risperidone in treatment of patients with schizophrenia and schizophreniform psychosis

AIM：To explore the difference on efficacy and social function between paliperidone extended-release tablets and risperidone in treatment of patients with schizophrenia and schizophreniform psychosis. METHODS：82 schizophrenic and schizophreniform psychosis patients were randomly contributed into groups treated with paliperidone extended-release tablets or with risperidone for 4 weeks.They were assessed with Positive and Negative Symptoms Scales（PANSS）,CGI-S and personal and social performance scale（PSP） in baseline,1st weekend,2nd weekend,3rd weekend and 4th weekend after treatment.RESULTS：In study group,the relative decreasing change of PANSS in the 4th weekend of treatment were all significantly higher than that of group of risperidone（P0.05 or 0.01）.The relative decreasing change of CGI-S in the 4th weekend of treatment was significantly higher than that of group of risperidone（P0.05）.The increasing changes of PSP in the 4th weekend of treatment were all significantly higher than that of group of risperidone（P0.01）.CONCLUSION：Paliperidone extended-release tablets are effective to improve symptoms,and social functions of patients with schizophrenia and schizophreniform psychosis.